Adoptive transfer of small numbers of DX5 + cells alleviates graft-versus-host disease in a murine model of semiallogeneic bone marrow transplantation: A potential role for NKT lymphocytes

Bone Marrow Transplantation

Volumn 35, Issue 2, 2005, Pages 191-197

  Margalit, M ^a   Ilan, Y ^a   Ohana, M ^b   Safadi, R ^a   Alper, R ^a   Sherman, Y ^a   Doviner, V ^a   Rabbani, E ^c   Engelhardt, D ^c   Nagler, A ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c Enzon Incorporated   (United States)

Author keywords

Adoptive transfer; Graft versus host disease; NKT lymphocytes; Semiallogeneic bone marrow transplantation

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 14; INTERLEUKIN 4;

ADOPTIVE TRANSFER; ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FLUORESCENCE ACTIVATED CELL SORTING; GRAFT VERSUS HOST REACTION; HELPER CELL; HISTOPATHOLOGY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INTESTINE INJURY; LIVER INJURY; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTE TRANSFER; LYMPHOID CELL LINE; MALE; MORTALITY; MOUSE; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SKIN DISEASE; SPLEEN CELL; SURVIVAL RATE; T CELL DEPLETION; TH2 CELL;

ADOPTIVE TRANSFER; ANIMALS; BONE MARROW TRANSPLANTATION; CD4-CD8 RATIO; CYTOKINES; FEMALE; GRAFT VS HOST DISEASE; IMMUNE TOLERANCE; KILLER CELLS, NATURAL; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MODELS, ANIMAL; SPLEEN; T-LYMPHOCYTES; TH2 CELLS; TRANSPLANTATION, HOMOLOGOUS;

EID: 19944433117     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704719     Document Type: Article

References (33)

1. Ferrara JLM, Deeg HJ. Graft versus host disease. N Engl J Med 1991; 324: 667-672.
2. Vogelsang GB. Graft versus host disease: implications from basic immunology for prophylaxis and treatment. Cancer Treat Res 1997; 77: 87-97.
3. Taylor PA, Lees CJ, Blazar BT. The infusion of ex-vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99: 3493-3499.
4. Cohen JL, Trenado A, Vasey D et al. CD4+CD25+ immuneregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med 2002; 196: 401-406.
5. Hoffmann P, Ermann J, Edinger M et al. Donor-type CD4+CD25+ regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389-399.
6. Edinger M, Hoffmann P, Ermann J et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9: 1144-1150.
7. Jones SC, Murphy GF, Korngold R. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD4+CD25+ T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant 2003; 9: 243-256.
8. Lan F, Zeng D, Higuchi M et al. Predominance of NK1.1+TCRαβ+ or DX5+TCRαβ+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: 'natural suppressor' cells. J Immunol 2001; 167: 2087-2096.
9. Higuchi M, Zeng D, Shizuru J et al. Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NKT cells and clonal deletion. J Immunol 2002; 169: 5564-5570.
10. Zeng D, Lewis D, Dejbakhsh-Jones S et al. Bone marrow NK1.1- and NK1.1+ T cells reciprocally regulate acute graft-versus-host-disease. J Exp Med 1999; 189: 1073-1081.
11. Lan F, Zeng D, Higuchi M et al. Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host-disease: the role of CD1-reactive natural killer T cells. Biol Blood Marrow Transplant 2003; 9: 355-363.
12. Gumperz JE, Brenner MB. CD1-specific T cells in microbial immunity. Curr Opin Immunol 2001; 13: 471-478.
13. Mars LT, Laloux V, Goude K et al. Cutting edge: V á14Já281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice. J Immunol 2002; 168: 6007-6011.
14. Sharif S, Arreaza GA, Zucker P, Delovitch TL. Regulatory natural killer T cells protect against spontaneous and recurrent type I diabetes. Ann NY Acad Sci 2002; 958: 77-88.
15. Kawano T, Cui J, Koezuka Y et al. CD1d-restricted and TCR-mediated activation of Vá14 NKT cells by glycosylceramides. Science 1997; 278: 1626-1629.
16. Chen H, Paul WE. Cultured NK1.1+CD4+ T cells produce large amounts of IL-4 and IFNγ upon activation by anti-CD3 or CD1. J Immunol 1997; 159: 2240.
17. Crispe IN. Hepatic T cells and liver tolerance. Nat Rev Immunol 2003; 3: 51-62.
18. Smyth MJ, Crowe NY, Hayakawa Y et al. NKT cells - conductors of tumor immunity? Curr Opin Immunol 2002; 14: 165-171.
19. Kaneko Y, Harada M, Kawano T et al. Augmentation of V á14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J Exp Med 2000; 191: 105-114.
20. Lee PT, Putnam A, Benlagha K et al. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 2002; 110: 747-748.
21. Terabe M, Matsui S, Noben-Trauth N et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000; 1: 515-520.
22. Moodycliffe AM, Nghiem D, Clydesdale G, Ullrich SE. Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol 2000; 1: 521-525.
23. Ilan Y, Gotsman I, Pines M et al. Induction of oral tolerance in splenocyte recipients toward pretransplant antigens amelio-rates chronic graft versus host disease in a murine model. Transplantation 2000; 95: 3613-3619.
24. Nagler A, Ohana M, Alper R et al. Induction of oral tolerance in bone marrow transplantation recipients suppresses graft-versus-host disease in a semi-allogeneic mouse model. Bone Marrow Transplant 2003; 32: 363-369.
25. Johnson BD, Dagher N, Stankowski WC et al. Donor natural killer (NK1.1+) cells do not play a role in the suppression of GVHD or in the mediation of GVL reactions after DLI. Biol Blood Marrow Transplant 2001; 7: 589-595.
26. Taylor PA, Noelle RJ, Blazar BR. CD4+CD25+ immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 2001; 193: 1311-1318.
27. Wilson MT, Singh AK, Van Kaer L. Immunotherapy with ligands of natural killer cells. Trends Mol Med 2002; 8: 225-231.
28. Murphy WJ, Longo DL. The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation. Immunol Rev 1997; 157: 167-176.
29. Kolb HJ, Schmid C, Chen X et al. Adoptive immunotherapy in chimeras with donor lymphocytes. Acta Haematol 2003; 110: 110-120.
30. Wayne AS, Barrett AJ. Allogenenic hematopoietic stem cell transplantation for myeloproliferative disorders and myelodysplastic syndromes. Hematol Oncol Clin North Am 2003; 17: 1243-1260.
31. Crispe IN, Dao T, Klugewitz K et al. The liver as a site of T-cell apoptosis: graveyard, or killing field? Immunol Rev 2000; 174: 47-62.
32. Betz GT, Altrnan JD, Doherty PC. Characteristics of virus-specific CD8+ T cells in the liver during the control and resolution phases of influenza pneumonia. Proc Nad Acad Sci USA 1998; 95: 13812-13817.
33. Baker J, Vernerts MR, Shizuru JA, Negrin RS. Expansion of cytolytic D8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to IFN γ production. Blood 2001; 97: 2923-2931.